MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat. Med. 2023, 29, 115-126

Jiri Neuzil; Jakub Rohlena; Lukas Werner; Zuzana Bielcikova

doi:10.3390/cancers15184476

MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat. Med. 2023, 29, 115-126

Cancers (Basel). 2023 Sep 8;15(18):4476. doi: 10.3390/cancers15184476.

Authors

Jiri Neuzil^{1

2

3

4}, Jakub Rohlena², Lukas Werner², Zuzana Bielcikova^{4

5}

Affiliations

¹ School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia.
² Institute of Biotechnology, Czech Academy of Sciences, 252 50 Prague, Czech Republic.
³ Faculty of Science, Charles University, 128 00 Prague, Czech Republic.
⁴ First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.
⁵ General University Hospital, Charles University, 128 08 Prague, Czech Republic.

Abstract

A recent paper published in Nature Medicine reported on the Phase I clinical trial of a mitochondria-targeting anti-cancer agent IACS-01059 in patients with acute myeloid leukemia (AML) and solid tumors [...].